Inovio Long Term Debt vs Current Deferred Revenue Analysis
INO Stock | USD 12.10 0.09 0.75% |
Inovio Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Inovio Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inovio Pharmaceuticals is a good investment. Please check the relationship between Inovio Pharmaceuticals Long Term Debt and its Current Deferred Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
Long Term Debt vs Current Deferred Revenue
Long Term Debt vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inovio Pharmaceuticals Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Inovio Pharmaceuticals' Long Term Debt and Current Deferred Revenue is -0.31. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Inovio Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Inovio Pharmaceuticals' Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Inovio Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Long Term Debt i.e., Inovio Pharmaceuticals' Long Term Debt and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | -0.31 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Long Term Debt
Long-term debt is a debt that Inovio Pharmaceuticals has held for over one year. Long-term debt appears on Inovio Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Inovio Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Inovio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 5th of May 2024, Sales General And Administrative To Revenue is likely to grow to 60.05, while Issuance Of Capital Stock is likely to drop about 9.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 1.8M | 10.3M | 832.0K | 790.4K | Interest Expense | 1.9M | 1.3M | 1.2M | 1.2M |
Inovio Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Inovio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inovio Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
Total Current Liabilities | 32.0M | 41.7M | 65.7M | 96.9M | 42.6M | 23.4M | |
Total Stockholder Equity | 3.4M | 461.1M | 399.7M | 222.4M | 117.3M | 95.2M | |
Property Plant And Equipment Net | 26.6M | 24.1M | 29.0M | 18.0M | 14.5M | 7.5M | |
Net Debt | 77.3M | (211.7M) | (38.1M) | (14.3M) | 15.9M | 16.7M | |
Retained Earnings | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.6B) | (1.5B) | |
Accounts Payable | 7.6M | 1.5M | 24.8M | 80.9M | 4.6M | 7.3M | |
Cash | 22.2M | 250.7M | 71.1M | 46.3M | 14.3M | 13.6M | |
Non Current Assets Total | 49.8M | 68.6M | 47.5M | 33.3M | 19.8M | 28.2M | |
Cash And Short Term Investments | 89.5M | 411.6M | 401.3M | 253.0M | 145.3M | 92.0M | |
Net Receivables | 2.0M | 19.1M | 8.0M | 11.7M | 2.4M | 3.9M | |
Common Stock Shares Outstanding | 8.2M | 12.9M | 17.4M | 19.9M | 22.2M | 28.0M | |
Liabilities And Stockholders Equity | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
Non Current Liabilities Total | 106.6M | 36.9M | 30.5M | 29.3M | 13.0M | 12.1M | |
Other Current Assets | 2.6M | 40.5M | 39.1M | 50.5M | 5.4M | 6.9M | |
Other Stockholder Equity | 742.6M | 1.4B | 1.6B | 1.7B | 1.7B | 1.8B | |
Total Liab | 138.5M | 78.6M | 96.3M | 126.2M | 55.6M | 35.5M | |
Property Plant And Equipment Gross | 26.6M | 24.1M | 48.0M | 18.0M | 35.3M | 37.1M | |
Total Current Assets | 94.2M | 471.2M | 448.4M | 315.2M | 153.1M | 103.0M | |
Accumulated Other Comprehensive Income | 472.6K | (256.2K) | (282.2K) | (698.7K) | (662.6K) | (629.5K) | |
Intangible Assets | 3.7M | 3.1M | 2.6M | 2.1M | 2.4M | 2.3M | |
Other Current Liab | 22.1M | 37.9M | 38.4M | 13.2M | 18.7M | 19.7M | |
Other Liab | 9.1M | 206.4K | 111.2K | 32.0K | 36.9K | 35.0K | |
Non Currrent Assets Other | (5.4M) | 22.2M | (1.5M) | (1.6M) | 605.3K | 635.6K | |
Other Assets | 2.7M | 43.6M | 1.4M | 684.0K | 1.0 | 0.95 | |
Common Stock Total Equity | 101.4K | 186.9K | 217.4K | 253.1K | 227.8K | 216.4K | |
Common Stock | 101.4K | 186.9K | 217.4K | 253.1K | 22.8K | 21.7K | |
Property Plant Equipment | 12.8M | 11.3M | 17.5M | 7.7M | 8.9M | 5.2M | |
Current Deferred Revenue | 257.2K | 124.1K | 46.6K | 21.6K | 24.9K | 23.6K | |
Short Term Investments | 67.3M | 160.9M | 330.2M | 206.7M | 131.0M | 85.0M | |
Net Tangible Assets | (10.8M) | 447.5M | 386.5M | 209.7M | 241.2M | 159.6M | |
Retained Earnings Total Equity | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.3B) | (1.3B) | |
Capital Surpluse | 742.6M | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B |
Inovio Pharmaceuticals Implied Volatility | 96.62 |
Inovio Pharmaceuticals' implied volatility exposes the market's sentiment of Inovio Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharmaceuticals stock will not fluctuate a lot when Inovio Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inovio Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inovio Pharmaceuticals' short interest history, or implied volatility extrapolated from Inovio Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Inovio Stock analysis
When running Inovio Pharmaceuticals' price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.09) | Revenue Per Share 0.038 | Quarterly Revenue Growth (0.18) | Return On Assets (0.32) | Return On Equity (0.80) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.